Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo

NIMA-related kinase 2B has been known to be an important centrosome regulatory factor. The aim of this study was to investigate the effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel. We detected the expression of NIMA-related kinase 2B messenger RNA in MCF-10 cells,...

Full description

Saved in:
Bibliographic Details
Main Authors: Yahong Wang, Honghong Shen, Quangui Yin, Tongxian Zhang, Ziyu Liu, Wei Zhang, Yun Niu
Format: Article
Language:English
Published: SAGE Publishing 2017-04-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317699754
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849414013410082816
author Yahong Wang
Honghong Shen
Quangui Yin
Tongxian Zhang
Ziyu Liu
Wei Zhang
Yun Niu
author_facet Yahong Wang
Honghong Shen
Quangui Yin
Tongxian Zhang
Ziyu Liu
Wei Zhang
Yun Niu
author_sort Yahong Wang
collection DOAJ
description NIMA-related kinase 2B has been known to be an important centrosome regulatory factor. The aim of this study was to investigate the effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel. We detected the expression of NIMA-related kinase 2B messenger RNA in MCF-10 cells, including MCF-10A, MCF-10AT, MCF-10DCIS.com , and MCF-10CA1a. The influence of NIMA-related kinase 2B in nude mouse was also detected. The association between NIMA-related kinase 2B and clinicopathological factors was explored in invasive ductal carcinoma tissues. NIMA-related kinase 2B was lowly expressed in the precancerous cells, MCF-10A and MCF-10AT, and it was highly expressed in carcinomatous cells, MCF-10DCIS.com and MCF-10CA1a. The upregulation of NIMA-related kinase 2B can introduce the growth of MCF-10AT cells, knockdown of NIMA-related kinase 2B could remarkably inhibit cell proliferation in MCF-10DCIS.com and MCF-10 CA1a cells. Comparing the volume of the xenografts in nude mouse, we found that the tumors treated by NIMA-related kinase 2B small interfering RNA associated with paclitaxel were the smallest among all the groups. Expression of NIMA-related kinase 2B messenger RNA was associated with higher histological grades, positive lymph node, and high Ki67 index (>20%). The partial response rates were 75.0% in NIMA-related kinase 2B negative (NIMA-related kinase 2B−) patients and 15.8% in NIMA-related kinase 2B++ patients. The progressive disease rates were 10.0% in NIMA-related kinase 2B− patients and 52.6% in NIMA-related kinase 2B++ patients ( p  = 0.002). Our findings suggested that NIMA-related kinase 2B could play a role in the development and progression of breast cancer. Combination treatment using NIMA-related kinase 2B small interfering RNA and paclitaxel might be a novel potential therapy method for breast cancer.
format Article
id doaj-art-944734d24dd940cab96dccc56e7ccaf0
institution Kabale University
issn 1423-0380
language English
publishDate 2017-04-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-944734d24dd940cab96dccc56e7ccaf02025-08-20T03:33:57ZengSAGE PublishingTumor Biology1423-03802017-04-013910.1177/1010428317699754Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivoYahong Wang0Honghong Shen1Quangui Yin2Tongxian Zhang3Ziyu Liu4Wei Zhang5Yun Niu6Department of Radiotherapy, Tianjin Huanhu Hospital, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, ChinaDepartment of Internal Medicine, WuQing Hospital, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, ChinaNIMA-related kinase 2B has been known to be an important centrosome regulatory factor. The aim of this study was to investigate the effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel. We detected the expression of NIMA-related kinase 2B messenger RNA in MCF-10 cells, including MCF-10A, MCF-10AT, MCF-10DCIS.com , and MCF-10CA1a. The influence of NIMA-related kinase 2B in nude mouse was also detected. The association between NIMA-related kinase 2B and clinicopathological factors was explored in invasive ductal carcinoma tissues. NIMA-related kinase 2B was lowly expressed in the precancerous cells, MCF-10A and MCF-10AT, and it was highly expressed in carcinomatous cells, MCF-10DCIS.com and MCF-10CA1a. The upregulation of NIMA-related kinase 2B can introduce the growth of MCF-10AT cells, knockdown of NIMA-related kinase 2B could remarkably inhibit cell proliferation in MCF-10DCIS.com and MCF-10 CA1a cells. Comparing the volume of the xenografts in nude mouse, we found that the tumors treated by NIMA-related kinase 2B small interfering RNA associated with paclitaxel were the smallest among all the groups. Expression of NIMA-related kinase 2B messenger RNA was associated with higher histological grades, positive lymph node, and high Ki67 index (>20%). The partial response rates were 75.0% in NIMA-related kinase 2B negative (NIMA-related kinase 2B−) patients and 15.8% in NIMA-related kinase 2B++ patients. The progressive disease rates were 10.0% in NIMA-related kinase 2B− patients and 52.6% in NIMA-related kinase 2B++ patients ( p  = 0.002). Our findings suggested that NIMA-related kinase 2B could play a role in the development and progression of breast cancer. Combination treatment using NIMA-related kinase 2B small interfering RNA and paclitaxel might be a novel potential therapy method for breast cancer.https://doi.org/10.1177/1010428317699754
spellingShingle Yahong Wang
Honghong Shen
Quangui Yin
Tongxian Zhang
Ziyu Liu
Wei Zhang
Yun Niu
Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
Tumor Biology
title Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
title_full Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
title_fullStr Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
title_full_unstemmed Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
title_short Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo
title_sort effect of nima related kinase 2b on the sensitivity of breast cancer to paclitaxel in vitro and vivo
url https://doi.org/10.1177/1010428317699754
work_keys_str_mv AT yahongwang effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT honghongshen effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT quanguiyin effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT tongxianzhang effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT ziyuliu effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT weizhang effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo
AT yunniu effectofnimarelatedkinase2bonthesensitivityofbreastcancertopaclitaxelinvitroandvivo